0.4421
12.46%
-0.0629
Dopo l'orario di chiusura:
.44
-0.0021
-0.48%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.505
Aprire:
$0.5045
Volume 24 ore:
891.60K
Relative Volume:
0.88
Capitalizzazione di mercato:
$951.02K
Reddito:
-
Utile/perdita netta:
$-22.56M
Rapporto P/E:
-0.2291
EPS:
-1.93
Flusso di cassa netto:
$-16.12M
1 W Prestazione:
-34.99%
1M Prestazione:
-51.60%
6M Prestazione:
-77.90%
1 anno Prestazione:
-23.91%
Cyclacel Pharmaceuticals Inc Stock (CYCC) Company Profile
Nome
Cyclacel Pharmaceuticals Inc
Settore
Industria
Telefono
908-517-7330
Indirizzo
200 CONNELL DRIVE, BERKELEY HEIGHTS, NJ
Cyclacel Pharmaceuticals Inc Stock (CYCC) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2022-07-18 | Ripresa | Oppenheimer | Outperform |
2020-04-27 | Ripresa | ROTH Capital | Buy |
2018-09-07 | Iniziato | Ladenburg Thalmann | Buy |
2015-10-16 | Iniziato | H.C. Wainwright | Buy |
2010-02-04 | Iniziato | Roth Capital | Buy |
2009-10-28 | Iniziato | Merriman | Buy |
2008-08-12 | Iniziato | Piper Jaffray | Buy |
2008-03-12 | Reiterato | Cantor Fitzgerald | Buy |
2008-03-12 | Reiterato | Collins Stewart | Buy |
2008-03-12 | Reiterato | Needham & Co | Buy |
2007-11-27 | Reiterato | Cantor Fitzgerald | Buy |
2007-08-10 | Reiterato | Cantor Fitzgerald | Buy |
2007-06-04 | Reiterato | Needham & Co | Buy |
2007-04-23 | Iniziato | Lazard Capital | Buy |
2007-04-10 | Iniziato | Cantor Fitzgerald | Buy |
Mostra tutto
Cyclacel Pharmaceuticals Inc Borsa (CYCC) Ultime notizie
Cyclacel stock plunges to 52-week low at $0.6 amid market challenges - Investing.com
Cyclacel stock plunges to 52-week low at $0.74 amid market challenges - Investing.com India
Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule - The Manila Times
Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium - ForexTV.com
Nasopharyngeal Cancer Market Report: Growth Forecast and Key - openPR
Sangamo Therapeutics, Cyclacel Pharma, GE Aerospace: 3 Stocks Retailers Are Most Bullish Tuesday Afternoon - Barchart
Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) Stock Sentiment: What’s Wall Street Saying? - Stocks Register
CYCCPCyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock Latest Stock News & Market Updates - StockTitan
Cyclacel Pharmaceuticals (CYCC) Price Target Increased by 11.56% to 13.94 - MSN
Cyclacel stock plunges to 52-week low, touches $0.8 By Investing.com - Investing.com Australia
Cyclacel stock plunges to 52-week low, touches $0.8 - Investing.com
CYCCCyclacel Pharmaceuticals, Inc Latest Stock News & Market Updates - StockTitan
Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium - The Manila Times
Cyclacel stock plunges to 52-week low at $0.95 amid market challenges - Investing.com Australia
Cyclacel stock plunges to 52-week low at $0.95 amid market challenges By Investing.com - Investing.com South Africa
Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study - ForexTV.com
Entero Therapeutics (NASDAQ:ENTO) Stock Quotes, Forecast and News Summary - Benzinga
(CYCCP) Trading Report - Stock Traders Daily
Cyclacel Pharmaceuticals (CYCC) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN
Cyclacel halts dividend on preferred stock - Investing.com
Cyclacel halts dividend on preferred stock By Investing.com - Investing.com Canada
Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference - ForexTV.com
Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter - ForexTV.com
Cyclacel Pharmaceuticals May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Benzinga
Cyclacel Pharmaceuticals Inc (CYCC)’s highs and lows: A closer look at its stock price fluctuations - US Post News
Metric Analysis: Cyclacel Pharmaceuticals Inc (CYCC)’s Key Ratios in the Limelight - The Dwinnex
You might want to take a look at Cyclacel Pharmaceuticals Inc (CYCC) now - SETE News
How To Trade (CYCCP) - Stock Traders Daily
Cyclacel Pharmaceuticals faces potential Nasdaq delisting - Investing.com India
Cyclacel Pharmaceuticals faces potential Nasdaq delisting By Investing.com - Investing.com UK
Geopark Ltd, Cyclacel Pharmaceuticals, Another 3 Companies Have A High Estimated Dividend Yield - Via News Agency
Cyclacel stock plunges to 52-week low at $1.13 amid market challenges - Investing.com
Cyclacel Pharmaceuticals faces Nasdaq delisting - Investing.com
Cyclacel Pharmaceuticals faces Nasdaq delisting By Investing.com - Investing.com UK
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q2 2024 Earnings Call Transcript - MSN
Cyclacel Pharmaceuticals changes its auditor - Investing.com
Cyclacel Pharmaceuticals changes its auditor By Investing.com - Investing.com UK
Cyclacel stock hits 52-week low at $1.21 amid market challenges - Investing.com
Cyclacel Pharmaceuticals Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Simply Wall St
Cyclacel Pharmaceuticals Inc Azioni (CYCC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Cyclacel Pharmaceuticals Inc Azioni (CYCC) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
Rombotis Spiro George | President and CEO |
Dec 21 '23 |
Buy |
3.31 |
6,070 |
20,122 |
68,658 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):